The same stock keeps pulling our engine back in

What the system saw

We're back in CRNX. Again. If you've been following along, you already know the Relative Strength Engine has taken multiple entries on this name over the past couple of weeks — and here comes another one. That's not a glitch. When a stock sits in the 96th percentile of relative strength over the past 63 days and keeps finding buyers at its 20-day moving average, the system keeps raising its hand. Today it did exactly that, with CRNX trading at $84.70 and sitting less than 1% above that 20-day support level. The proximity is almost surgical — today's low was $84.61, the 20-day sits at $83.97, and price is essentially resting right on top of it. Not drifting through it. Resting on it.

Why our Relative Strength Engine liked it

The core idea is straightforward: stocks outperforming nearly everything else in the market tend to keep doing it — especially when they pull back to a logical support level instead of breaking down. CRNX has earned that top-decile rank over a 63-day window, and it's holding the 20-day rather than falling through it. The volume dry-up score contributed to the signal too. Low-volume consolidation near support is often exactly what you want to see before the next leg higher. Now, a fair warning on the fundamentals: this is a biotech burning cash. Negative margins, negative ROE, no meaningful earnings. Analyst consensus is Buy, but the average price target is $84.86 — basically where it's trading right now. The Altman Z-Score is strong at 39.5, well clear of distress territory, but the Piotroski F-Score of 2/9 is weak. This isn't a value story, and the Relative Strength Engine isn't pretending it is — it's reading price behavior, not balance sheets. Still, it's worth knowing what's under the hood before you watch this one move.

The trade plan

The Relative Strength Engine entered at $84.70 with a stop at $83.57 — that's $1.13 of risk per share. Our system's 2R target sits at $86.97. We're putting about $4,997 behind it, which works out to 59 shares. The structure is clean: a tight stop just below the 20-day, a clear target above, and a name with a demonstrated track record of momentum. Conviction score came in at 67.2 out of 100 — solid, not a slam dunk. Worth noting: we already have existing CRNX positions running from earlier entries. This is the system doubling down on a name it keeps coming back to.

Position size: our paper account is putting about $4,997 (59 shares) into this trade, sized to risk roughly $67 if our stop is hit. This is what the system committed in its paper account — not a suggestion of how much you should put into any trade.

What could go wrong

A few things deserve a straight look. SPY is essentially flat today — up just 0.02% — so there's no broad tailwind doing any of the heavy lifting here. If the market slips, high-RS names can give back ground fast. The stop at $83.57 sits below the 20-day, but a decisive break of that level would flip the setup's entire logic. And it's worth being honest about where things stand: at Day 30 of this experiment, the system is trailing SPY by 1.9% on the same window, with a 0-for-10 win rate on closed trades. The open positions are doing real work — SNOW up 21.4%, CORT up 24.5% — but nothing has been booked yet. CRNX's earlier entries are small in the green. Whether any of those close out favorably is the question we're all watching.

One more thought before we go

At some point, CRNX either justifies all these entries or it doesn't. The Relative Strength Engine is making a repeated bet that this stock belongs at the front of the line. Now we wait to see if the market agrees — and whether one of these CRNX positions finally finds its way into the win column.